Is It Time To Revisit iRhythm Holdings (IRTC) After The Recent Share Price Slide?

• If you are wondering whether iRhythm Holdings at around US$113 still lines up with its underlying worth, you are not alone. This article is here to unpack that question clearly.
• The share price has recently been under pressure, with a 7 day return of 8.6% decline, a 30 day return of 25.7% decline, and a year to date return of 35.5% decline, even though the 1 year return sits at 12.2% and the 3 year return at 0.1%.
• These mixed returns sit against a backdrop of ongoing attention on iRhythm Holdings as a medical device name. Investors are watching how its technology and market position translate into long term adoption and commercial traction. Recent headlines have focused on its role in cardiac monitoring and broader healthcare trends, while also keeping questions about valuation firmly in view.
• Our valuation checks currently give iRhythm Holdings a score of 3 out of 6. This means there are areas where the share price and fundamentals appear more in line and others where they look less so. We will walk through the different valuation methods shortly, then finish with a broader way to frame what that score really means for long term investors.

iRhythm Holdings delivered 12.2% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry.

Approach 1: iRhythm Holdings Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a business could generate in the future and discounts those cash flows back to today to arrive at an estimated intrinsic value per share.

For iRhythm Holdings, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow (FCF) is about $31.6 million. Analyst estimates and extrapolated figures suggest FCF reaching about $544.9 million in 2035, with interim projections such as $54.9 million in 2026 and $186 million in 2028. All of these figures are discounted back to present value within the model.

Putting these cash flows together, the DCF arrives at an estimated intrinsic value of about $228.86 per share. Compared with the recent share price around $113, the model output implies the stock is about 50.6% undervalued on this cash flow view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests iRhythm Holdings is undervalued by 50.6%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for iRhythm Holdings.

Approach 2: iRhythm Holdings Price vs Sales

For a business where earnings are not yet a clean guide, the Price to Sales, or P/S, ratio is often a useful cross check because it focuses on how the market values each dollar of revenue rather than profit. Investors usually accept a higher or lower P/S depending on what they expect for future growth and how much risk they see in the business model, the balance sheet and the industry.

iRhythm Holdings currently trades on a P/S of 4.89x. That sits above the Medical Equipment industry average of 2.77x and also above the peer group average of 4.11x. Simply Wall St’s proprietary Fair Ratio for iRhythm, which is 3.91x, is designed to be more tailored than a simple peer or industry comparison because it incorporates factors such as the company’s earnings growth profile, profit margins, market capitalization, industry characteristics and stock specific risks.

Comparing the current 4.89x P/S to the 3.91x Fair Ratio suggests the shares are pricing in more optimism than this model would imply, so on this metric the stock screens as overvalued.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your iRhythm Holdings Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce Narratives. These are simply your story about iRhythm Holdings linked directly to a forecast and a fair value, where you set assumptions for future revenue, earnings and margins, and the model turns that story into numbers that sit alongside the current share price on Simply Wall St’s Community page, used by millions of investors.

With Narratives, you can see how your fair value compares to today’s price to help you decide whether the gap between them is big enough to act on. Those fair values update automatically when new information such as earnings, guidance changes or regulatory news is added to the platform.

For example, one investor might plug in assumptions close to the higher earnings and price target views, aligning their story with fair value around US$213 per share. Another might lean toward the lower earnings and price target views and land nearer US$158. Both Narratives can sit side by side so you can quickly see how different expectations about iRhythm’s growth, profitability and risks translate into very different views of what the company is worth.

Do you think there's more to the story for iRhythm Holdings? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com